Buy, Sell or Hold: Mind Medicine (MindMed) (MNMD-Q)

Home

Daily Stock Opinions and Ratings

Mind Medicine (MindMed) (MNMD-Q)

NASDAQ:MNMD

7.07

0.13 (1.87%) 1d

Nervous markets await Nvidia

PARTIAL BUY

Last month, they received therapy designation to use their LSD program that treats anxiety. Shares have since jumped 80%.

RISKY

He thought psychedelic drugs had a future, but it's in the past. A great spec, but warnings: stocks can go to zero.

Showing 1 to 2 of 2 entries

Mind Medicine (MindMed)(MNMD-Q) Rating

Ranking : 1 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 0

Stockchase rating for Mind Medicine (MindMed) is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Mind Medicine (MindMed)(MNMD-Q) Frequently Asked Questions

What is Mind Medicine (MindMed) stock symbol?

Mind Medicine (MindMed) is a American stock, trading under the symbol MNMD-Q on the NASDAQ (MNMD). It is usually referred to as NASDAQ:MNMD or MNMD-Q

Is Mind Medicine (MindMed) a buy or a sell?

In the last year, there was no coverage of Mind Medicine (MindMed) published on Stockchase.

Is Mind Medicine (MindMed) a good investment or a top pick?

Mind Medicine (MindMed) was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Mind Medicine (MindMed).

Why is Mind Medicine (MindMed) stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Mind Medicine (MindMed) worth watching?

In the last year, there was no coverage of Mind Medicine (MindMed) published on Stockchase.

What is Mind Medicine (MindMed) stock price?

On 2025-05-22, Mind Medicine (MindMed) (MNMD-Q) stock closed at a price of $7.07.

Most Recent Experts

Keith Richards

ValueTrend Wealth Management

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Kim Bolton

Black Swan Dexteritas

Stockchase Insights

5i Research

Jim Cramer - Mad Money

CNBC

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.